An incredible first day at #ASMMicrobe in Atlanta connecting with clients, fellow professionals, and friends, sharing insights, and discussing the latest advancements in microbiology and diagnostics. If you're attending, let us know so we can meet face to face! #ASMMicrobe2024 #MedicalDevices #IVDs #InVitroDiagnostics #HealthcareInnovation
MDC Associates, Inc.’s Post
More Relevant Posts
-
Just 48 hours now until the British Society for Antimicrobial Chemotherapy (BSAC) conference at London's QEII Centre🕒, and with the release of new 5 year National Action Plan on AMS📋, finding partnerships which can help drive AMS success are more key than ever before. Why not join us at stand 3 to chat about how bioMérieux can super power your antimicrobial stewardship efforts!!💪 Kate Donnachie Sarah Purnell #antimicrobialstewardship #diagnostics #dataandit 🚀
To view or add a comment, sign in
-
-
Join the conversation!
Endpreeclampsia.org is hosting a virtual chat with Dr. Rebecca Khan and Dr. Champa Woodham to discuss the new biomarker blood test for preeclampsia risk assessment. Join the conversation live or on-demand to learn about the clinical study and FDA indication, implementation of a novel test, and real-world impact captured by Dr. Woodham in practice. Follow the link to register: https://lnkd.in/g4yRdDtX #thermofisheremp
To view or add a comment, sign in
-
-
▶️ Diagnostics play a vital role in the informed prescription of antibiotics 💊. ▶️ Established antimicrobial susceptibility tests (AST) serve as reliable tools to assess resistance to antibiotics through phenotypic determination [6] ▶️ There are several solutions to support the AST performance available in the market. In this white paper 📄, we examine the topic ‘How to perform real-time antimicrobial susceptibility testing (AST).’ Read to learn more about the current diagnostic workflow vs rapid AST diagnostic workflow. 👇 #sysmexnordic
To view or add a comment, sign in
-
What’s evolved in #AntimicrobialStewardship since the Jim O’Neill report of 2016? 💡 Find out at #ECCMID2024 with bioMérieux’s Integrated Symposium “Tackling drug-resistant infections globally with rapid diagnostics: Advancements in Microbiology since the Jim O’Neill report” ◾ Keynote: “Societal impact of AMR, with an update since the publication of the O’Neill Report” by Lord O’Neill of Gatley ◾ “Inappropriate empirical treatments in Blood Stream Infections: where we stand and how to improve?” by Prof. Romney Humphries ◾ “How Clinical Decision Support Systems and Dashboards can support Antimicrobial Stewardship”: by Prof. Céline Pulcini 📅 It’s on April 28th from 16-17:30 at HALL 6 ROOM L Find out more about bioMérieux's program at ECCMID: https://lnkd.in/eGx-eFrF #ESCMIDGlobal #AntimicrobialStewardship #WeArebioMérieux
To view or add a comment, sign in
-
Physician executive. Extensive clinical, business, hospital, diagnostic lab & executive biomedical industry experience. CMO at bioMérieux for 11 years. Open to consultations, advisory roles & board positions.
Another solid clinical study showing the benefits of centralization of the bioMérieux 𝐕𝐈𝐑𝐓𝐔𝐎 𝐛𝐥𝐨𝐨𝐝 𝐜𝐮𝐥𝐭𝐮𝐫𝐞 (𝐁𝐂) 𝐬𝐲𝐬𝐭𝐞𝐦 for patients with Gram-negative bacteremia, in conjunction with Antimicrobial Stewardship and lab efficiency analysis: - 𝐝𝐞𝐜𝐫𝐞𝐚𝐬𝐞𝐝 𝐭𝐢𝐦𝐞 from BC draw to treatment change by 12.1 hours - 𝐝𝐞𝐜𝐫𝐞𝐚𝐬𝐞𝐝 𝐭𝐢𝐦𝐞 from pathogen ID to treatment change by 8.7 hours - 𝐠𝐫𝐞𝐚𝐭𝐞𝐫 duration of optimal antimicrobial therapy by 1 day - 𝐝𝐞𝐜𝐫𝐞𝐚𝐬𝐞𝐝 𝐭𝐢𝐦𝐞 to vancomycin de-escalation by 7.8 hours #diagnosticsispower https://lnkd.in/eVbbxY2Q
To view or add a comment, sign in
-
-
📣 Upcoming event alert! Thermo Fisher Scientific is organizing a webinar 💻 about effective use of PCT (procalcitonin) to manage older and at-risk patients: 📅June 12th, 2024 🕓16:00 CET Join this initiative for an insightful panel discussion on the effective use of Thermo Scientific B·R·A·H·M·S PCT (invaluable marker that helps assess bacterial infections and aids in antibiotic therapy for aging and frail patients). Learn from top experts how B·R·A·H·M·S PCT supports responsible antibiotic use in older populations. 👨Gaetan Gavazzi 👨Thomas M. File Jr. 👨Michael Bauer This webinar will be moderated by Mike Broyles, PharmD, Director of Medical Affairs for Thermo Fisher Scientific Biomarkers. Don‘t miss out this opportunity! Register now to secure your spot: 🔗 https://bit.ly/3X9olry #EuGMS #PCT #GeriatricMedicine #HealthcareInnovation #ThermoFisherScientific #Webinar #Learning
To view or add a comment, sign in
-
-
What’s evolved in #AntimicrobialStewardship since the Jim O’Neill report of 2016? 💡 Find out at #ECCMID2024 with bioMérieux’s Integrated Symposium “Tackling drug-resistant infections globally with rapid diagnostics: Advancements in Microbiology since the Jim O’Neill report” ◾ Keynote: “Societal impact of AMR, with an update since the publication of the O’Neill Report” by Lord O’Neill of Gatley ◾ “Inappropriate empirical treatments in Blood Stream Infections: where we stand and how to improve?” by Prof. Romney Humphries ◾ “How Clinical Decision Support Systems and Dashboards can support Antimicrobial Stewardship”: by Prof. Céline Pulcini 📅 It’s on April 28th from 16-17:30 at HALL 6 ROOM L Find out more about bioMérieux's program at ECCMID: https://lnkd.in/epqaPYJ3 #ESCMIDGlobal #AntimicrobialStewardship #ECCMID2024 #BeAGameChanger
Join bioMérieux's first Integrated Symposium at ECCMID 2024
share.biomerieux.com
To view or add a comment, sign in
-
Have you read the latest biannual CLSI AST News Update? It highlights current issues related to antimicrobial susceptibility testing (AST) and reporting. The CLSI Outreach Working Group (ORWG), under CLSI's Subcommittee on Antimicrobial Susceptibility Testing (AST), works to efficiently convey information regarding contemporary AST practices, recommendations, and resources to the clinical microbiology community. Read it here >> https://ow.ly/5zRH50QAbK6.
To view or add a comment, sign in
-
-
🌟 Join NG Biotech's Fight Against Antimicrobial Resistance! 🦠 Antimicrobial Resistance (AMR) is a global health crisis that demands swift and decisive action. At NG Biotech, we are committed to leading the charge in combating AMR by providing efficient and rapid diagnostic tools. 💪 Our mission is clear: to empower healthcare professionals with the tools they need to tackle AMR head-on. In the coming months, we are thrilled to announce the release of new tools that will further enhance our arsenal against this pressing threat. 🚀 Why are rapid diagnostics crucial in the fight against AMR? 🔍 Early Detection: Rapid diagnostic tools allow for the early detection of infectious agents and their susceptibility to antibiotics. This means faster treatment decisions, better patient outcomes, and reduced antibiotic misuse. 💡 Informed Choices: Healthcare professionals armed with precise and timely information can make informed choices about antimicrobial therapy. This not only saves lives but also helps preserve the effectiveness of these essential drugs. 🌐 Global Impact: Our commitment to developing innovative solutions transcends borders. Together with our partners and collaborators, we aim to make a global impact in the battle against AMR. 🤝 Join Us!: We invite you to join NG Biotech on this critical journey. Together, we can make a difference. Stay connected with NG Biotech for the latest updates. https://lnkd.in/e6HkcVV5 #AMR #AntimicrobialResistance #HealthcareInnovation #NGBiotech #RapidDiagnostics #HealthcareSolutions
ANTIMICROBIAL RESISTANCE
https://www.ngbiotech.com
To view or add a comment, sign in
-
About a month ago, we announced positive results from a randomized controlled clinical trial on suPAR-guided antibiotic treatment in sepsis at the European Shock Conference in Vienna. 💥 What is so revolutionary about the SUPERIOR study? 🤔 Some patients with only one qSOFA risk sign require early treatment to prevent progression, and the challenge is to find the ones that benefit from early treatment. The study shows that the measurement of suPAR in patients with one risk sign (1 point of qSOFA score) identifies a subgroup of patients at high risk of an unfavorable outcome and early deterioration if not treated. These patients receive significant benefits from early meropenem treatment, guided by suPARnostic®. So, by utilizing suPAR to direct sepsis treatment, hospitals can minimize antibiotic usage to those who will genuinely benefit from it, while also promptly initiating treatment to prevent the escalation to more critical stages of sepsis, leading to the potential for saving more lives! Visit our website: https://www.virogates.com/ #sepsis #antibiotics #suPAR
To view or add a comment, sign in
-